Fertility and Early Embryonic Development Toxicity of hzVSF‐v13 in Sprague–Dawley Rats
Journal of Applied Toxicology · 2026
DOI: 10.1002/jat.4898 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Toxicology, 2026. Verfasst von Ji-Seong Jeong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Developmental and Reproductive Toxicology Research, Korea Institute of Toxicology, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Embryonic Development, Fertility, Antibodies, Monoclonal, COVID-19 Drug Treatment. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation (NRF), Korea Institute of Toxicology.
Abstract (Originalsprache)
Humanized virus suppressing factor–variant 13 (hzVSF‐v13), a monoclonal IgG4 antibody, is a potential therapeutic candidate for COVID‐19. Although fertility and embryonic developmental toxicity studies are crucial for the safety evaluation of new drugs, the toxicological profile of hzVSF‐v13 remains unexplored. This study was performed to assess its effects on general toxicity, fertility, and early embryonic development in Sprague–Dawley rats administered intravenously once weekly at doses of 0, 25, 50, and 100 mg/kg. Males received the test article starting 4 weeks before mating and continuing until the day prior to sacrifice, while females were treated beginning 2 weeks prior to mating and continuing through the implantation. No treatment‐related effects were observed on general toxicological parameters, including body weight, food consumption, macroscopic findings, or organ weights in both sexes. Additionally, hzVSF‐v13 did not affect the mating performance, fertility, sperm analysis, or litter parameters in cesarean section at doses up to 100 mg/kg. Under the experimental conditions, the no‐observed‐adverse‐effect level (NOAEL) of hzVSF‐v13 for general toxicity, fertility, and early embryonic development was considered to be 100 mg/kg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Developmental and Reproductive Toxicology Research, Korea Institute of Toxicology, Daejeon, Republic of Korea.
- College of Veterinary Medicine, Chonnam National University, Gwangju, Republic of Korea.
- Laboratory Animal Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
- Center for Biomedical Diagnostic Research, Korea Institute of Toxicology, Daejeon, Republic of Korea.
- ImmuneMed, Inc., Seoul, Republic of Korea.
- Korea Preclinical Evaluation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Förderung
- National Research Foundation (NRF)
- Korea Institute of Toxicology
Zitieren
APA
Jeong, J. S., Kim, S. Y., Lee, J., Lee, S. J., Ham, O., Kim, W., Im, W. J., Park, S., Ko, K. C., Kim, J. C., & Kim, Y. B. (2026). Fertility and Early Embryonic Development Toxicity of hzVSF‐v13 in Sprague–Dawley Rats. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4898
Vancouver
Jeong JS, Kim SY, Lee J, Lee SJ, Ham O, Kim W, et al. Fertility and Early Embryonic Development Toxicity of hzVSF‐v13 in Sprague–Dawley Rats. Journal of Applied Toxicology. 2026. doi:10.1002/jat.4898
BibTeX
@article{Jeong2026,
author = {Jeong, Ji-Seong and Kim, Sang-Yun and Lee, Jinsoo and Lee, Seung-Jin and Ham, Onju and Kim, Woojin and Im, Wan-Jung and Park, Sungman and Ko, Kyong-Cheol and Kim, Jong-Choon and Kim, Yong-Bum},
title = {Fertility and Early Embryonic Development Toxicity of hzVSF‐v13 in Sprague–Dawley Rats},
journal = {Journal of Applied Toxicology},
year = {2026},
doi = {10.1002/jat.4898}
}
EUVIMED